Publication: 3367

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
      QxMD      Google Scholar   
Citation:
Leukemia vol 35 (9) 2539-2551
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
11
Parents:
2778   2779  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Novartis  
Grants:
U10CA180821, U10CA180882, U24CA196171, U10CA032291, U10CA041287, U10CA077651, U10CA077658, U10CA180791, U10CA180836, U10CA180850, U10CA180867, UG1CA233338, U10CA180863 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG).  
Corr. Author:
 
Authors:
                                                                 
Networks:
CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007   
Study
CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
midostaurin, FLT3-mutant, acute myeloid leukemia